Order Article Reprints

Tsai C-Y, Ko H-J, Chiou S-J, Lai Y-L, Hou C-C, Javaria T, Huang Z-Y, Cheng T-S, Hsu T-I, Chuang J-Y, et al. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. International Journal of Molecular Sciences. 2021; 22(11):5907. https://doi.org/10.3390/ijms22115907

Tsai, Cheng-Yu, Huey-Jiun Ko, Shean-Jaw Chiou, Yu-Ling Lai, Chia-Chung Hou, Tehseen Javaria, Zi-Yi Huang, Tai-Shan Cheng, Tsung-I Hsu, Jian-Ying Chuang, and et al. 2021. "NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition" International Journal of Molecular Sciences 22, no. 11: 5907. https://doi.org/10.3390/ijms22115907

Tsai, C.-Y., Ko, H.-J., Chiou, S.-J., Lai, Y.-L., Hou, C.-C., Javaria, T., Huang, Z.-Y., Cheng, T.-S., Hsu, T.-I., Chuang, J.-Y., Kwan, A.-L., Chuang, T.-H., Huang, C.-Y. F., Loh, J.-K., & Hong, Y.-R. (2021). NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. International Journal of Molecular Sciences, 22(11), 5907. https://doi.org/10.3390/ijms22115907